Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL30330327 | 0.97 | NCF1 (0.52) | NCF1GNAO1GNAI3GNAI1ACHE | |
| Cyanide SCHEMBL30330503 | 0.93 | NCF1 (0.48) | NCF1GNAO1GNAI3GNAI1ACHE | |
| SCHEMBL25809268 | 0.91 | NCF1 (0.46) | NCF1GNAO1GNAI3GNAI1ACHE | |
| SCHEMBL23251417 | 0.87 | — | — | |
| SCHEMBL255098 | 0.87 | — | — | |
| SCHEMBL13479302 | 0.87 | — | — | |
| Acetic Acid SCHEMBL30329842 | 0.87 | GNAI3 (0.51) | NCF1GNAO1GNAI3GNAI1ACHE | |
| SCHEMBL26042799 | 0.87 | OPRL1 (0.46) | NCF1GNAO1GNAI3GNAI1ACHE | |
| SCHEMBL26705170 | 0.87 | NCF1 (0.43) | NCF1GNAO1GNAI3GNAI1ACHE | |
| SCHEMBL24319800 | 0.86 | NCF1 (0.62) | NCF1GNAO1GNAI3GNAI1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102906159-A | Amine polymers as bile acid sequestrants | RELYPSA INC | 2013-01-30 | — | — | CN | claimed |
| CN-102858817-A | Crosslinked polyvinylamines, polyallylamines and ethyleneimines for use as bile acid sequestrants | RELYPSA INC | 2013-01-02 | — | — | CN | claimed |
| US-4386009-A | TRANSITION METAL CARBONYL AND TERTIARY AMINE CATALYTIC SYSTEM | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF ENERGY (US) | 1983-05-31 | — | — | US | claimed |
| WO-2024127022-A1 | HETEROCYCLIC COMPOUNDS TARGETING THE NUDT5 PROTEIN | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024076670-A2 | TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020221-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240016738-A1 | LIPID NANOPARTICLES | ETHERNA IMMUNOTHERAPIES NV (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20240016738-A1 | LIPID NANOPARTICLES | ETHERNA IMMUNOTHERAPIES NV (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11874434-B2 | Ophthalmic devices comprising photochromic materials with reactive substituents | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-7241745-B2 | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives | ASTELLAS PHARMA GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | BIEDERMANN ELFI | 2007-06-21 | — | — | US | disclosed |
| US-7232825-B2 | Phenylaminopyrimidine derivatives and methods of use | CHEN GUOQING P | 2007-06-19 | — | — | US | disclosed |
| WO-2006042848-A9 | GROWTH HORMONE CONJUGATES | NOVO NORDISK AS (DK) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1194418-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHODS FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma KG (DE) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078735-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-12-28 | — | — | WO | disclosed |
| CN-1152263-A | Zeolite SSZ-41 | CHEVRON USA INC (US) | 1997-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016738-A1 | LIPID NANOPARTICLES | CETP, NPC1L1, PLTP | NCF1 1056/4885GNAO1 3727/4885GNAI3 534/4885 |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | ALK, TYMP, PDCD1 | NCF1 1570/4885GNAO1 2623/4885GNAI3 2959/4885 |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | BTK, SYK, LCK | NCF1 1598/4885GNAO1 638/4885GNAI3 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.